Svenja Ehrlich
Bernhard Nocht Institute for Tropical Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Svenja Ehrlich.
Immunology Letters | 2000
Jochen Hühn; Svenja Ehrlich; Bernhard Fleischer; Arne von Bonin
CD26 or dipeptidylpeptidase IV (DPP IV) is a cell surface protease involved in T cell activation. It is a type II transmembrane glycoprotein consisting of a large extracellular part, a single transmembrane region and a short cytoplasmic tail without any common signalling motifs. To eluciate the mechanisms involved in CD26-mediated signalling we have constructed C-terminal deletion mutants of the human CD26 molecule and transfected them into murine T cell hybridomas. Stimulation experiments show that most of the extracellular part of CD26 can be deleted without affecting its costimulatory activity. The membrane proximal glycosylation rich region of CD26 is sufficient to transduce costimulatory signals. Activation of T cells via CD26, however, is not mediated by the important T cell receptor associated adaptor proteins LAT and TRIM as shown in colocalization assays.
Journal of The American Society of Nephrology | 2005
Andreas Lang; Dirk Benke; Frank Eitner; Daniel R. Engel; Svenja Ehrlich; Minka Breloer; Emma E. Hamilton-Williams; Sabine Specht; Achim Hoerauf; Jürgen Floege; Arne von Bonin; Christian Kurts
Heat shock proteins (Hsp) are ubiquitous intracellular proteins that can be released in various forms of cellular stress. Some Hsp, such as Hsp60, have been shown to stimulate directly T cell-mediated immune responses in vitro. Here, it is demonstrated that Hsp60 is released from the kidneys and excreted into the urine of mice with nephrotoxic nephritis (NTN), a model of rapidly progressive glomerulonephritis. For examining the functional relevance of Hsp60 release, this protein was injected into mice with subnephritogenic NTN, in which only transient proteinuria and minimal organ damage occur that do not progress to terminal kidney failure. Injection of Hsp60 strikingly aggravated disease, as evidenced by global glomerular necrosis, tubulointerstitial damage, and complete anuria after 10 to 12 d. This effect was mediated neither by endotoxin contaminations of Hsp60 nor by autologous antibodies. It was strictly T cell dependent but not associated with a systemic Th1/Th2 shift. Thus, Hsp60 is an endogenous mediator stimulating immune effector mechanisms that contribute to the progression of NTN. These findings demonstrate in vivo that Hsp60 fulfills criteria of immunologic danger signals and suggest that such signals may be involved in immune-mediated kidney disease.
European Journal of Immunology | 2007
Minka Breloer; Birte Kretschmer; Katja Lüthje; Svenja Ehrlich; Uwe Ritter; Thomas Bickert; Christiane Steeg; Simon Fillatreau; Kai Hoehlig; Vassiliki Lampropoulou; Bernhard Fleischer
The transmembrane glycoprotein CD83 has been described as a specific maturation marker for dendritic cells and several lines of evidence suggest that CD83 regulates thymic T cell maturation as well as peripheral T cell activation. Here we show for the first time that CD83 is involved also in the regulation of B cell function. CD83 is up‐regulated on activated B cells in vivo, specifically in the draining lymph nodes of Leishmania major‐infected mice. The ubiquitous transgenic (Tg) expression of CD83 interferes with Leishmania‐specific T cell‐dependent and with T cell‐independent antibody production. This defect is restricted to the B cell population since the antigen‐specific T cell response of CD83Tg mice to L. major infection is unchanged. The defective immunoglobulin (Ig) response is due to Tg expression of CD83 on the B cells because wild‐type B cells display normal antigen‐specific responses in CD83Tg hosts and CD83Tg B cells do not respond to immunization in a mixed wild‐type/CD83Tg bone marrow chimera. Finally, the treatment of non‐Tg C57BL/6 mice with anti‐CD83 mAb induces a dramatic increase in the antigen‐specific IgG response to immunization, thus demonstrating a regulatory role for naturally induced CD83 on wild‐type B cells.
Scandinavian Journal of Immunology | 2003
M. Wolenski; Sven O. Cramer; Svenja Ehrlich; Christiane Steeg; Bernhard Fleischer; A. von Bonin
CD83 is a marker molecule for mature dendritic cells (DCs) but is also substantially expressed on activated T cells in humans and mice. Its function is unknown, but CD83 knockout mice show an impaired thymic maturation of CD4‐positive cells and soluble CD83 inhibits partially antigen‐specific responses in vitro pointing to a role of CD83 in the immune system. Here we show that CD83‐positive T cells produce strongly increased amounts of interferon‐γ and interleukin‐2. In contrast, constitutive expression of CD83 on DCs alters neither the activation of DCs following addition of lipopolysaccharide nor the ability to present antigenic peptides. Thus, the expression of CD83 on T cells has direct functional consequences for tuning the activation threshold.
Medical Microbiology and Immunology | 2003
Matthias Wolenski; Sven O. Cramer; Svenja Ehrlich; Christiane Steeg; Gudrun Großschupff; Klara Tenner-Racz; Paul Racz; Bernhard Fleischer; Arne von Bonin
CD83 is used as a marker for mature dendritic cells (DC) in man. We have developed a new monoclonal antibody (mAb), Michel-17, that specifically recognizes mouse CD83. We show that murine CD83 is expressed mainly on mature DC and on activated T cells. Histological analysis of serial spleen sections revealed a CD83 expression pattern resembling that of MIDC-8, a known murine DC marker molecule. In contrast to other costimulatory receptors, cross-linking of CD83 with the mAb Michel-17 on DC or T cells does not induce any activation signals. Our data describe for the first time the expression pattern of murine CD83, which is comparable to that of human CD83.The unique mAb Michel-17 will help to elucidate the biological functions of the CD83 molecule in more detail.
PLOS ONE | 2007
Birte Kretschmer; Katja Lüthje; Andreas H. Guse; Svenja Ehrlich; Friedrich Koch-Nolte; Friedrich Haag; Bernhard Fleischer; Minka Breloer
The murine transmembrane glycoprotein CD83 is an important regulator for both thymic T cell maturation and peripheral T cell responses. Recently, we reported that CD83 also has a function on B cells: Ubiquitous transgenic (Tg) expression of CD83 interfered with the immunoglobulin (Ig) response to infectious agents and to T cell dependent as well as T cell independent model antigen immunization. Here we compare the function of CD83Tg B cells that overexpress CD83 and CD83 mutant (CD83mu) B cells that display a drastically reduced CD83 expression. Correlating with CD83 expression, the basic as well as the lipopolysaccharide (LPS) induced expression of the activation markers CD86 and MHC-II are significantly increased in CD83Tg B cells and reciprocally decreased in CD83mu B cells. Wild-type B cells rapidly upregulate CD83 within three hours post BCR or TLR engagement by de novo protein synthesis. The forced premature overexpression of CD83 on the CD83Tg B cells results in reduced calcium signaling, reduced Ig secretion and a reciprocally increased IL-10 production upon in vitro activation. This altered phenotype is mediated by CD83 expressed on the B cells themselves, since it is observed in the absence of accessory cells. In line with this finding, purified CD83mu B cells displayed a reduced IL-10 production and slightly increased Ig secretion upon LPS stimulation in vitro. Taken together, our data strongly suggest that CD83 is expressed by B cells upon activation and contributes to the regulation of B cell function.
Immunology Letters | 2008
Birte Kretschmer; Katja Lüthje; Svenja Ehrlich; Anke Osterloh; Melanie Piédavent; Bernhard Fleischer; Minka Breloer
The transmembrane glycoprotein CD83 is rapidly upregulated on murine and human DC upon maturation and therefore a costimulatory function for T cell activation has been suggested. Studies employing human APC indeed showed that CD83 expression was positively correlated to the stimulatory capacity of the APC. Murine APC that were CD83 deficient however, did not display a reduced capacity to activate T cells. To elucidate this contradiction, we thoroughly compared the stimulatory capacity of CD83-overexpressing and CD83-deficient APC. Here we show that CD83 expression levels on APC did not affect the capacity of the APC to activate CD8(+) T cells. CD83 expression levels did not significantly affect CD4(+) T cell activation in vivo, but a weak positive correlation of CD83 expression with CD4(+) T cell activation was observed in vitro under suboptimal stimulation conditions. As CD83 expression also positively correlated with MHC-II but not with MHC-I expression, this differential stimulation specifically of CD4(+) T cells could be explained by a higher density of MHC-II peptide complexes on the APC surface. Taken together, our results strongly suggest that CD83 does not deliver crucial costimulatory signals to murine T cells.
European Journal of Immunology | 1995
Arne von Bonin; Svenja Ehrlich; Georg Malcherek; Bernhard Fleischer
European Journal of Immunology | 1996
Minka Breloer; Svenja Ehrlich; Bernhard Fleischer; Arne von Bonin
36th Annual Meeting of the American-Society-of-Nephrology | 2003
Christian Kurts; Andreas Lang; Thilo Krüger; Dirk Benke; Emma E. Hamilton-Williams; M Wirtz; Svenja Ehrlich; A von Bonin; K Assmann; Frank Eitner; Jürgen Floege